A first-in-human phase 1 study of the SHP2 inhibitor BBP-398 in patients with advanced solid tumors.
Saved in:
| Title: | A first-in-human phase 1 study of the SHP2 inhibitor BBP-398 in patients with advanced solid tumors. |
|---|---|
| Authors: | Falchook G; Sarah Cannon Research Institute at HealthONE, Denver, CO, USA., Braganca Xavier C; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Van Veenhuyzen D; BridgeBio, Palo Alto, CA, USA., Malhotra J; City of Hope Comprehensive Cancer Center, Duarte, CA, USA., Sadeghi S; David Geffen School of Medicine at UCLA, Los Angeles, CA, USA., Kalebasty AR; University of California, Irvine, Irvine, CA, USA., Wood L; BridgeBio, Palo Alto, CA, USA., Rahman F; BridgeBio, Palo Alto, CA, USA., Li E; PharmaStat, Fremont, CA, USA., Pak Y; BridgeBio, Palo Alto, CA, USA., Khalil M; The University of Alabama at Birmingham, O'Neal Comprehensive Cancer Center, Birmingham, AL, USA., Spira AI; NEXT Oncology, Fairfax, VA, USA., Sommerhalder D; NEXT Oncology, San Antonio, TX, USA., Garrido-Laguna I; University of Utah Huntsman Cancer Institute, Salt Lake City, UT, USA., Hong DS; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. dshong@mdanderson.org. |
| Source: | NPJ precision oncology [NPJ Precis Oncol] 2026 Feb 28; Vol. 10 (1). Date of Electronic Publication: 2026 Feb 28. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Springer Nature Country of Publication: England NLM ID: 101708166 Publication Model: Electronic Cited Medium: Print ISSN: 2397-768X (Print) Linking ISSN: 2397768X NLM ISO Abbreviation: NPJ Precis Oncol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
